| European Case Law Identifier: | ECLI:EP:BA:2017:T108911.20171212 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 12 December 2017 | ||||||||
| Case number: | T 1089/11 | ||||||||
| Application number: | 03766057.8 | ||||||||
| IPC class: | C12N 5/0735 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | METHOD FOR THE AMPLIFICATION OF A POXVIRUS UNDER SERUM FREE CONDITIONS | ||||||||
| Applicant name: | Bavarian Nordic A/S | ||||||||
| Opponent name: | Emergent Product Development UK Limited Sanofi Pasteur Transgene S.A. |
||||||||
| Board: | 3.3.08 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Admission of documents (68) and (69) - (no) Added matter - (no) Clarity - (yes) Sufficiency of disclosure - (yes) Priority - (yes) Novelty - (yes) Inventive step - (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t111089eu1.html
Date retrieved: 17 May 2021